Immuneering Corporation (IMRX) is a Biotechnology company in the Healthcare sector, currently trading at $5.41. It has a SharesGrow Score of 54/100, indicating a mixed investment profile with 3 out of 7 criteria passed.
Analyst consensus target is IMRX = $12 (+121.8% upside).
Valuation: IMRX trades at a trailing Price-to-Earnings (P/E) of -4.4 (S&P 500 average ~25).
Net income is $56M (loss), growing at -4.8%/yr. Net profit margin is 0% (thin). Gross margin is 50.1% (+0 pp trend).
Balance sheet: total debt is $4M against $218M equity (Debt-to-Equity (D/E) ratio 0.02, conservative). Current ratio is 17.5 (strong liquidity). Debt-to-assets is 1.6%. Total assets: $232M.
Analyst outlook: 7 / 11 analysts rate IMRX as buy (64%) — moderate consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 100/100 (Pass), Moat 46/100 (Partial), Future 73/100 (Pass), Income ?/100 (Fail).
